A Phase 3 interventional study of HRS9531 Tablet and HRS9531 Tablet Placebo in Chronic Management of Body Weight, sponsored by Fujian Shengdi Pharmaceutical Co., Ltd.. Recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-13.
Sponsored by Fujian Shengdi Pharmaceutical Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study aims to evaluate the efficacy and safety of HRS9531 tablets compared with placebo in reducing body weight in overweight or obese subjects after 52 weeks of treatment.
Fujian Shengdi Pharmaceutical Co., Ltd. is the lead sponsor of 66 studies on the registry; 24 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HRS9531 tablet.
Drug: HRS9531 Tablet
HRS9531 tablet placebo.
Drug: HRS9531 Tablet Placebo
HRS9531 tablet.
HRS9531 tablet placebo.
Percentage change from baseline in body weight after 52 weeks of treatment
Time frame: After 52 weeks of treatment.
Proportion of subjects with weight loss of ≥ 5% from baseline in body weight after 52 weeks of treatment
Time frame: After 52 weeks of treatment.
Proportion of subjects with weight loss of ≥ 10% from baseline in body weight after 52 weeks of treatment
Time frame: After 52 weeks of treatment.
Proportion of subjects with weight loss of ≥ 15% from baseline in body weight after 52 weeks of treatment
Time frame: After 52 weeks of treatment.
Proportion of subjects with weight loss of ≥ 20% from baseline in body weight after 52 weeks of treatment
Time frame: After 52 weeks of treatment.
Change from baseline in waist circumference after 52 weeks of treatment
Time frame: After 52 weeks of treatment.
Change from baseline in body weight after 52 weeks of treatment
Time frame: After 52 weeks of treatment.
Change from baseline in BMI (Body Mass Index) after 52 weeks of treatment
Time frame: After 52 weeks of treatment.
Change from baseline in blood pressure after 52 weeks of treatment
Time frame: After 52 weeks of treatment.
Change from baseline in fasting plasma glucose after 52 weeks of treatment
Time frame: After 52 weeks of treatment.
Change from baseline in fasting serum insulin after 52 weeks of treatment
Time frame: After 52 weeks of treatment.
Change from baseline in glycosylated hemoglobin after 52 weeks of treatment
Time frame: After 52 weeks of treatment.
Change from baseline in blood lipid after 52 weeks of treatment
Time frame: After 52 weeks of treatment.
Change from baseline in blood uric acid after 52 weeks of treatment
Time frame: After 52 weeks of treatment.
Number of treatment serious adverse events (SAEs) within 57 weeks
Time frame: Within 57 weeks.
Number of treatment adverse events (AEs) within 57 weeks
Time frame: Within 57 weeks.
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for Oct 2027, 15 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: HRS9531
Fujian Shengdi Pharmaceutical Co., Ltd. →